Amikacin bayesian forecasting in critically III patients with sepsis and cirrhosis

Therapeutic Drug Monitoring

Volumn 19, Issue 3, 1997, Pages 271-276

  Lugo, Gustavo ^a,b   Castaneda Hernandez G ^a,b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Amikacin; Aminoglycosides; Bayesian forecasting; Cirrhotic; Septic

Indexed keywords

ADRENALIN; AMIKACIN; NORADRENALIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMORBIDITY; DOSE CALCULATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TREATMENT PLANNING;

AMIKACIN; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CRITICAL ILLNESS; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; SEPSIS;

EID: 0345267238     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199706000-00005     Document Type: Article

References (31)

1. Miyagawa CI. Aminoglycosides in the intensive care units: an old drug in a dynamic environment. New Horizons 1993;2:172-180
2. Garrison MN, Zaske DE, Rotschafer JC. Aminoglycosides: another perspective. DICP Ann Pharmacother 1990;24:267-272.
3. Noone P, Pearsen TMC, Pattison JR, Slack RCB, Garfield D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:447-481.
4. Moore RD, Smith CR, Leitman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-448.
5. Gill MA, Cheetham TC, Chenella FC, et al. Matched case control study of adjusted versus non-adjusted gentamicin dosing in perforated and gangrenous appendicitis. Ther Drug Monit 1986;8:451-456.
6. Zaske DE, Bootman JL, Solem LB, Strate RG. Increased burn patients survival with individualized dosages of gentamicin. Surgery 1982;91:142-149.
7. Marik PE, Havlik Y, Monteagudo FSE, Lipman J.The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice daily dosing regimens. J Anti Chemo 1991;27(suppl C) 81-89.
8. Zaske DE, Cipolle RJ, Strate RG. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980;87:164-169.
9. Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ. Altered aminoglycoside pharmacokinetics in the critically ill. Anesth Intens Care 1988;16:418-422.
10. Hassan E, Ober J. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Crit Care Med 1986;14:394-398.
11. Flint LM, Gott J, Short L, Richardson D, Polk HC. Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia. Arch Surg 1985;120:99-103.
12. Burton ME, Brater C, Chen SP, Day BR, Huber JP, Vasko RM. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985;37:349-357.
13. Gill MA, Okamoto MP, Nakahiro RK, Chin A, Inagaki K, Sclar DA. Pharmacokinetic population parameters for aminoglycosides in cholecystitis patients. Ther Drug Monit 1992;14:107-111.
14. McClellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as internal estimates. Ther Drug Monit 1989;11:431-436.
15. Moreau R, Hadengue A, Soupison T, et al. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992;20:746-750.
16. Toll DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and amonoglycoside clearance in critically ill septic patients. Crit Care Med 1993;21:248-251.
17. Lugo G, Castañeda-Hernández G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill septic patients. Crit Care Med. In press.
18. Triginer C, Izquierdo Y, Fernández R, et al. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol 1991;40:297-302.
19. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, (The methylprednisolone severe sepsis study group). Sepsis syndrome: a valid clinical entity. Crit Care Med 1989;17:389-393.
20. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
21. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophagel varices. Br J Surg 1973;60: 646-649.
22. Jelliffe WR, Schumitzky A, Van Guilder M. User manual for the nonparametric EM program for population pharmacokinetic modeling, version 1.02. University of Southern California School of medicine, Los Angeles, Calif.
23. Jelliffe WR, Schumitzky A, Van Guilder M. User manual for the USC*PACK and population PC programs. Laboratory of applied pharmacokinetics. University of Southern California School of Medicine, Los Angeles, Cal.
24. Deter RG, Krausse AE, Penn F, Nahaczewski EA. Comparison of aminoglycoside clearance and calculated serum creatinine clearance. Ther Drug Monit 1989;11:155-161.
25. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-511.
26. Sarubbi FA, Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978;89:612-618.
27. Platt DR, Matthews SJ, Sevka MJ, et al. Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. Clin Pharm 1982;1:361-365.
28. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer aided drug dosage. Comput Biomed Res 1972;5:441-459.
29. Marik PE, Lipman J, Scribante J, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Agents Chemother 1991;28:753-764.
30. Beaucaire G, Leroy O, Beuscart C, Kaup P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27(suppl C):91-103.
31. Zhanel GG, Hobban DJ, Handing GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother 1991;25:153-163.